First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor of YAP/TEAD, in Pts With Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors With NF2 Mutations | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

AACR 2023 Conference Coverage

First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor of YAP/TEAD, in Pts With Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors With NF2 Mutations

By AACR 2023 Conference Coverage FEATURING Timothy Yap

By AACR 2023 Conference Coverage FEATURING Timothy Yap

67 views

May 4, 2023

Comments 0

Login to view comments. Click here to Login